Clinicopathologic Characteristics of Non-small Cell Lung Cancer in Patients with Smoking-related Chronic Obstructive Pulmonary Disease

Overview

Journal Gen Thorac Cardiovasc Surg

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2018 Sep 7

PMID 30187259

Citations 3

Authors

Ryo Maeda

Masaki Tomita

Katsuo Usuda

Hidetaka Uramoto

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to clarify the clinicopathologic characteristics of non-small cell lung cancer (NSCLC) patients with smoking-related chronic obstructive pulmonary disease (COPD) and to evaluate the biological behavior of this disease. We investigated the association between smoking-related COPD, the recurrence-free proportion (RFP) and the clinicopathological features of clinical stage I NSCLC patients.

Methods: Between 2005 and 2014, 218 consecutive patients with clinical stage I NSCLC underwent complete resection with lobectomy or greater and systematic lymph node dissection. Differences in categorical outcomes were evaluated by the χ test. RFPs were estimated using the Kaplan-Meier method, and differences were evaluated using the log-rank test.

Results: The 5-year RFP of clinical stage I NSCLC patients with smoking-related COPD was 55%, which was significantly lower than in those without smoking-related COPD (85%; p < 0.001). Postoperative pathological factors, including moderate or poor histological differentiation, intratumoral vascular invasion and lymph node metastasis, were detected more often in patients with smoking-related COPD. In adenocarcinoma patients, the 5-year RFP of patients with smoking-related COPD was 47%, which was significantly lower than in those without smoking-related COPD (87%; p < 0.001). The presence of a solid component was more frequently found in patients with smoking-related COPD (p = 0.007).

Conclusion: Clinical stage I NSCLC patients with smoking-related COPD have histologically more invasive tumors than those without smoking-related COPD.

Citing Articles

Is There a Link between Chronic Obstructive Pulmonary Disease and Lung Adenocarcinoma? A Clinico-Pathological and Molecular Study.

Lunardi F, Nardo G, Lazzarini E, Tzorakoleftheraki S, Comacchio G, Fonzi E J Pers Med. 2024; 14(8).

PMID: 39202030 PMC: 11355616. DOI: 10.3390/jpm14080839.

Evaluation of Microscopic Tumour Extension in Localized Stage Non-Small-Cell Lung Cancer for Stereotactic Radiotherapy Planning.

Schmitt M, Aussenac L, Seitlinger J, Lindner V, Noel G, Antoni D Cancers (Basel). 2022; 14(5).

PMID: 35267589 PMC: 8909894. DOI: 10.3390/cancers14051282.

Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles.

Qian S, Golubnitschaja O, Zhan X EPMA J. 2019; 10(4):365-381.

PMID: 31832112 PMC: 6882964. DOI: 10.1007/s13167-019-00194-x.

References

Malkinson A . Role of inflammation in mouse lung tumorigenesis: a review. Exp Lung Res. 2005; 31(1):57-82. DOI: 10.1080/01902140490495020. View

Licker M, Widikker I, Robert J, Frey J, Spiliopoulos A, Ellenberger C . Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends. Ann Thorac Surg. 2006; 81(5):1830-7. DOI: 10.1016/j.athoracsur.2005.11.048. View

Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C . Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg. 2006; 81(6):1988-95. DOI: 10.1016/j.athoracsur.2006.01.021. View

Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N . Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006; 132(4):769-75. DOI: 10.1016/j.jtcvs.2006.02.063. View

Mantovani A, Allavena P, Sica A, Balkwill F . Cancer-related inflammation. Nature. 2008; 454(7203):436-44. DOI: 10.1038/nature07205. View

Young R, Hopkins R, Christmas T, Black P, Metcalf P, Gamble G . COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009; 34(2):380-6. DOI: 10.1183/09031936.00144208. View

Punturieri A, Szabo E, Croxton T, Shapiro S, Dubinett S . Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009; 101(8):554-9. PMC: 2669099. DOI: 10.1093/jnci/djp023. View

Barletta J, Yeap B, Chirieac L . Prognostic significance of grading in lung adenocarcinoma. Cancer. 2009; 116(3):659-69. PMC: 2846761. DOI: 10.1002/cncr.24831. View

Takahashi H, Ogata H, Nishigaki R, Broide D, Karin M . Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell. 2010; 17(1):89-97. PMC: 2818776. DOI: 10.1016/j.ccr.2009.12.008. View

10.

Adcock I, Caramori G, Barnes P . Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration. 2011; 81(4):265-84. DOI: 10.1159/000324601. View

11.

Vestbo J, Hurd S, Agusti A, Jones P, Vogelmeier C, Anzueto A . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012; 187(4):347-65. DOI: 10.1164/rccm.201204-0596PP. View

12.

Powell C, Halmos B, Nana-Sinkam S . Update in lung cancer and mesothelioma 2012. Am J Respir Crit Care Med. 2013; 188(2):157-66. PMC: 3778761. DOI: 10.1164/rccm.201304-0716UP. View

13.

Koike T, Koike T, Yoshiya K, Tsuchida M, Toyabe S . Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013; 146(2):372-8. DOI: 10.1016/j.jtcvs.2013.02.057. View

14.

Zhai R, Yu X, Shafer A, Wain J, Christiani D . The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest. 2013; 145(2):346-353. PMC: 3913301. DOI: 10.1378/chest.13-1176. View

15.

Qian Q, Shi X, Lei Z, Zhan L, Liu R, Zhao J . Methylated +58CpG site decreases DCN mRNA expression and enhances TGF-β/Smad signaling in NSCLC cells with high metastatic potential. Int J Oncol. 2014; 44(3):874-82. DOI: 10.3892/ijo.2014.2255. View

16.

Luis Izquierdo J, Resano P, El Hachem A, Graziani D, Almonacid C, Sanchez I . Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors. Int J Chron Obstruct Pulmon Dis. 2014; 9:1053-8. PMC: 4200171. DOI: 10.2147/COPD.S68766. View

17.

King P . Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med. 2015; 4(1):68. PMC: 4518022. DOI: 10.1186/s40169-015-0068-z. View

18.

Travis W, Brambilla E, Burke A, Marx A, Nicholson A . Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015; 10(9):1240-1242. DOI: 10.1097/JTO.0000000000000663. View

19.

Detterbeck F, Chansky K, Groome P, Bolejack V, Crowley J, Shemanski L . The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2016; 11(9):1433-46. DOI: 10.1016/j.jtho.2016.06.028. View

20.

Tsubota N, AYABE K, Doi O, Mori T, Namikawa S, Taki T . Ongoing prospective study of segmentectomy for small lung tumors. Study Group of Extended Segmentectomy for Small Lung Tumor. Ann Thorac Surg. 1999; 66(5):1787-90. DOI: 10.1016/s0003-4975(98)00819-4. View